Rapport Therapeutics (NASDAQ:RAPP) Research Coverage Started at Citizens Jmp

Citizens Jmp started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a research report released on Tuesday, MarketBeat Ratings reports. The brokerage issued a mkt outperform rating on the stock.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $8.63 on Tuesday. The company has a 50 day moving average price of $11.33 and a two-hundred day moving average price of $17.18. The company has a market capitalization of $314.96 million and a PE ratio of -0.62. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $29.74.

Insider Buying and Selling

In other Rapport Therapeutics news, CFO Troy A. Ignelzi acquired 9,900 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares of the company’s stock, valued at $99,990. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Wendy B. Young bought 6,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were bought at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the completion of the acquisition, the director now directly owns 6,000 shares in the company, valued at approximately $61,260. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the third quarter worth $34,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Rapport Therapeutics in the 4th quarter valued at about $34,000. Deutsche Bank AG acquired a new stake in shares of Rapport Therapeutics in the 4th quarter valued at about $41,000. New York State Common Retirement Fund bought a new stake in shares of Rapport Therapeutics in the fourth quarter valued at about $62,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Rapport Therapeutics during the fourth quarter worth about $66,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.